Exelixis (NASDAQ:EXEL) is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.
The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer. In addition, Exelixis markets TURALIO® (pexidartinib), a first-in-class colony-stimulating factor-1 receptor (CSF1R) inhibitor indicated for symptomatic tenosynovial giant cell tumor. Exelixis maintains a diverse pipeline of targeted oncology candidates, several of which are in mid-to-late-stage clinical trials exploring indications such as prostate cancer and ovarian cancer.
Headquartered in Alameda, California, Exelixis operates research and development facilities in the United States and collaborates with international partners to extend its global reach. The company has a strategic commercialization alliance with Ipsen for territories outside the United States, and it engages in collaborations with other pharmaceutical and biotech firms to expand its portfolio and access complementary technologies. Exelixis’s products are available in North America, Europe, and select Asian markets.
Founded in 1994, Exelixis went public in 2000 and has since evolved into a leader in oncology drug discovery and development. The company is led by President and Chief Executive Officer Michael M. Morrissey, whose tenure has emphasized pipeline growth and global commercialization. Under his leadership, Exelixis continues to invest in research initiatives, clinical development programs and strategic partnerships aimed at bringing new cancer therapies to patients worldwide.